Regulatory Flexibility Ushers in a New Era of Modernizing Cancer Clinical Trials

The U.S. Food and Drug Administration (FDA) has announced its final guidance on relaxing laboratory test value criteria to facilitate cancer clinical trial patient recruitment and improve clinical success rates, with the guidelines slated for release in July 2026. This guidance, developed in collaboration with the American Society of Clinical Oncology (ASCO) and the Friends of Cancer Research (FOCR), was finalized two years after the initial draft in early 2024. This change addresses industry concerns that overly conservative lab value cutoffs have been hindering patient access to clinical trials. With increased regulatory flexibility, significant changes are expected in the clinical design strategies of pharmaceutical companies.

Practical Relaxation of Renal and Hematological Criteria

The guidance recommends relaxing renal and hematological screening criteria to more realistic levels. Specifically, for substances with low potential for renal toxicity, the guidelines specify that patients with a creatinine clearance (CrCl) of 30 mL/min or higher should be eligible for clinical trial participation. Hematological indicators will also be assessed flexibly, taking into account underlying conditions and safety risks, rather than excluding patients based solely on numerical values. These adjustments are expected to increase the participation of elderly patients and those with impaired renal function, contributing to the collection of data that more closely reflects real-world clinical settings.

Redefining the Role of CTCAE and Improving Clinical Design

This guidance addresses the practice of misusing the Common Terminology Criteria for Adverse Events (CTCAE) as an absolute measure for selecting clinical trial patients. The core message is that CTCAE should be used as a tool for post-hoc management and reporting of adverse events, and should not serve as a barrier to patient screening. Drug developers should design laboratory test value criteria scientifically, based on the mechanism of action (MoA) and safety profile of the new drug. This will help reduce unnecessary screening failure rates and improve clinical success rates.

Financial Benefits of Reduced Clinical Costs and Accelerated Drug Launch

From the perspective of biotech companies and investors, this regulatory change will lead to financial benefits in the form of shorter clinical trial timelines and reduced costs. Since more than 80% of delays in cancer clinical trials are due to patient recruitment delays, improving lab value cutoffs is a solution to address this high-cost structure. In particular, for small and medium-sized biotech companies with limited funding, accelerating patient recruitment provides an opportunity to preserve their runway and accelerate the achievement of subsequent milestones. This will help alleviate additional funding pressures caused by clinical delays and enable more efficient allocation of resources.

Improved Approval Success Rates Through the Collection of Real-World Data

Finally, the data collected using the relaxed criteria will be beneficial in demonstrating the efficacy and safety of drugs in real-world settings. In the past, many drugs have failed to achieve market success after approval due to unexpected adverse events or reduced efficacy in clinical trials involving overly healthy patients. The availability of data from a more diverse patient population will facilitate the demonstration of efficacy in patients with unmet needs, thereby increasing the commercial value. As a result, this will enhance the persuasiveness of presentations to the FDA Advisory Committee (AdComm) and accelerate market penetration after approval, providing a competitive advantage.